OGN logo

Organon & Co. (OGN)$13.43

Market Cap: 2.27 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Organon & Co. (OGN).

HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready

Valuation

19.2x

EV/FCF, 5.2% FCF yield

Quality

2.0%

ROIC, 8.7% FCF margin

Growth

-1.0%

5Y sales (revenue) CAGR

Balance sheet

11.5x

Debt/equity, 1.8x current ratio

Superinvestors

1

Top: Kahn Brothers Group (5.9%)

Strengths to research

  • Return on equity is strong at 24.9%.

Watchouts

  • Five-year revenue trend is negative at -1.0%.
  • Debt/equity is high at 11.5x.
Annual data: 7 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for OGN.

Grade F
18
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
OGN
Target
Organon & Co.$2.3B18.7x19.2x2.0%-1.0%8.7%53.3%N/AN/A
NAMSNewamsterdam Pharma Co Nv$2.2B-20.6x-11.7x-29.7%N/A-657.8%N/AN/AN/A
ACHCAcadia Healthcare Co.$2.1B-1.9x-10.2x-24.8%9.7%-13.3%N/AN/AN/A
PGNYProgyny Inc.$2.0B38.3x9.9x11.3%30.2%14.9%23.6%-1.2xN/A
IMVTImmunovant Inc.$2.6B-12.3x-4.1x-59.3%N/AN/AN/AN/AN/A
LIVNLivaNova PLC$2.0B-16.6x9.9x-15.4%8.2%12.5%67.7%-1.1xN/A
ENOVEnovis Corp.$2.0B-1.2x161.2x-42.5%14.9%0.9%59.8%5.7xN/A
TVTXTravere Therapeutics Inc.$1.9B-153.2x47.9x-22.2%19.9%7.7%N/AN/AN/A
QDELQuidelOrtho Corp.$1.9B-0.7x-53.0x-24.5%10.4%-3.0%N/AN/AN/A

Financial Charts

No financial data available for OGN (annual).

1 superinvestors own OGN

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Kahn Brothers Group

Kahn Brothers Group

5,536,993$33M5.88%0.0%